...
首页> 外文期刊>EFSA Journal >Scientific Opinion on the substantiation of health claims related to Lactobacillus rhamnosus GR‐1 (ATCC 55826) in combination with Lactobacillus reuteri RC‐14 (ATCC 55845) and defence against vaginal pathogens by increasing the proportion of lactobacilli and/or decreasing the proportion of potentially pathogenic bacteria and/or yeasts (ID 945) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
【24h】

Scientific Opinion on the substantiation of health claims related to Lactobacillus rhamnosus GR‐1 (ATCC 55826) in combination with Lactobacillus reuteri RC‐14 (ATCC 55845) and defence against vaginal pathogens by increasing the proportion of lactobacilli and/or decreasing the proportion of potentially pathogenic bacteria and/or yeasts (ID 945) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

机译:关于证实与鼠李糖乳杆菌GR-1(ATCC 55826)和罗伊氏乳杆菌RC-14(ATCC 55845)有关的健康主张的科学意见,并通过增加乳酸杆菌比例和/或降低潜在的比例来防御阴道病原符合1924/2006号法规(EC)第13(1)条的致病细菌和/或酵母菌(ID 945)

获取原文
   

获取外文期刊封面封底 >>

       

摘要

This opinion addresses the scientific substantiation of health claims in relation to Lactobacillus rhamnosus GR-1 (ATCC 55826) in combination with Lactobacillus reuteri RC-14 (ATCC 55845) and defence against vaginal pathogens by increasing the proportion of lactobacilli and/or decreasing the proportion of potentially pathogenic bacteria and/or yeasts. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claim is Lactobacillus rhamnosus GR-1 (ATCC 55826) in combination with Lactobacillus reuteri RC-14 (ATCC 55845). The Panel considers that Lactobacillus rhamnosus GR-1 (ATCC 55826) and Lactobacillus reuteri RC-14 (ATCC 55845) are sufficiently characterised. The claimed effect is “vaginal health/flora”. The target population is assumed to be the general female population. From the clarifications provided by Member States, the Panel assumes that the claimed effect refers to defence against vaginal pathogens by increasing the number of lactobacilli and/or 1 On request from the European Commission, Question No EFSA-Q-2008-1732, adopted on 08 April 2011. Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus L?vik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuh?user-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
机译:该意见解决了关于鼠李糖乳杆菌GR-1(ATCC 55826)与罗伊氏乳杆菌RC-14(ATCC 55845)组合的健康主张的科学依据,并通过增加乳酸杆菌比例和/或降低比例来防御阴道病原体潜在的致病细菌和/或酵母菌。科学依据是成员国在第13条健康声明综合清单中提供的信息,以及EFSA从成员国或直接从利益相关者那里获得的参考。作为健康声明主题的食品成分是鼠李糖乳杆菌GR-1(ATCC 55826)与罗伊氏乳杆菌RC-14(ATCC 55845)的组合。小组认为,鼠李糖乳杆菌GR-1(ATCC 55826)和罗伊氏乳杆菌RC-14(ATCC 55845)具有足够的特征。声称的效果是“阴道健康/植物区系”。假定目标人群为普通女性人群。根据成员国提供的说明,小组认为所要求的效果是指通过增加乳酸杆菌和/或1的数量来防御阴道病原体1根据欧洲委员会的要求,于2007年5月1日通过的EFSA-Q-2008-1732问题2011年4月8日。小组成员:卡洛·阿戈斯托尼,让·路易·布雷森,苏珊·费尔威瑟·泰特,阿尔伯特·弗林,伊内斯·古利,汉努·科洪宁,帕格纳·拉久欧,马丁努斯·维维克,罗珊格拉·马尔凯利,安布罗伊斯·马丁,贝文·莫斯利,莫妮卡·纽厄斯-Berthold,Hildegard Przyrembel,Seppo Salminen,Yolanda Sanz,Sean(JJ)Strain,Stephan Strobel,Inge Tetens,DanielTomé,Hendrik van Loveren和Hans Verhagen。

著录项

  • 来源
    《EFSA Journal》 |2011年第6期|共15页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 食品工业;
  • 关键词

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号